Telos Biotech

Telos Biotech is developing a platform technology to address cellular senescence and exhaustion in cell therapies. The company's lead asset, Telovance™, is a protein-based intervention administered during the ex-vivo expansion phase of cell manufacturing to maintain telomere length. This approach aims to improve the durability, potency, and long-term efficacy of cell therapies across a range of diseases. As a pre-clinical, pre-revenue private company, Telos operates as a Bio PipeCo, partnering with other cell therapy developers to integrate its technology into their manufacturing processes.

Telovance™, a protein complex delivered during ex-vivo cell expansion to safely lengthen telomeres, aiming to combat cellular senescence and exhaustion to improve the durability and performance of cell therapies.

Competition includes other companies targeting T-cell exhaustion and senescence through metabolic engineering, epigenetic modulation, or alternative telomere maintenance strategies. Telos's differentiation lies in its specific focus on direct telomere lengthening as a seamless manufacturing add-on.